Acute Myelogenous Leukemia [clinicaltrials_resource:6092f80113dd6cc62cd4650efc5112f5]
Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) [clinicaltrials:NCT00015587]clinicaltrials:NCT00038831Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes [clinicaltrials:NCT00038870]Study of Gelonin Purging of Autologous Stem Cells for Transplantation [clinicaltrials:NCT00043810]Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant [clinicaltrials:NCT00044733]Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia [clinicaltrials:NCT00044889]Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT00064584]clinicaltrials:NCT00074737Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) [clinicaltrials:NCT00074750]PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP [clinicaltrials:NCT00088231]Investigation of Clofarabine in Acute Leukemias [clinicaltrials:NCT00098033]Study of Troxatylâ„¢ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT00104468]Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT00106600]Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia [clinicaltrials:NCT00116467]Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia [clinicaltrials:NCT00136422]High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) [clinicaltrials:NCT00136448]A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [clinicaltrials:NCT00136461]Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation [clinicaltrials:NCT00144677]Differentiation Induction in Acute Myelogenous Leukemia [clinicaltrials:NCT00175812]clinicaltrials:NCT00184054Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies [clinicaltrials:NCT00270881]MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia [clinicaltrials:NCT00274248]Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [clinicaltrials:NCT00285259]A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy [clinicaltrials:NCT00297921]Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. [clinicaltrials:NCT00299780]clinicaltrials:NCT00303667Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor [clinicaltrials:NCT00304720]clinicaltrials:NCT00315705clinicaltrials:NCT00317642AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia [clinicaltrials:NCT00321581]A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia [clinicaltrials:NCT00324220]clinicaltrials:NCT00326170clinicaltrials:NCT00334074An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia [clinicaltrials:NCT00346632]clinicaltrials:NCT00360672clinicaltrials:NCT00373529Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation [clinicaltrials:NCT00374933]clinicaltrials:NCT00378534clinicaltrials:NCT00382590clinicaltrials:NCT00382954
condition [clinicaltrials_vocabulary:condition]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Acute Myelogenous Leukemia [clinicaltrials_resource:6092f80113dd6cc62cd4650efc5112f5]
Bio2RDF identifier
6092f80113dd6cc62cd4650efc5112f5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6092f80113dd6cc62cd4650efc5112f5
identifier
clinicaltrials_resource:6092f80113dd6cc62cd4650efc5112f5
title
Acute Myelogenous Leukemia
@en
label
Acute Myelogenous Leukemia [clinicaltrials_resource:6092f80113dd6cc62cd4650efc5112f5]
@en